To determine whether vascular endothelial growth factor (VEGF) expression and microvessel density are predictive of prognosis in cases of invasive cervical cancer, correlations among VEGF expression, microvessel density, and clinicopathological parameters were identified. VEGF expression was evaluated in 50 cervical cancer samples by immunohistochemical staining. 
Introduction
Cervical cancer is still associated with high mortality rates among women worldwide (1). Tumor neovascularization plays a crucial role in the development of solid tumors including cervical cancers. Vascular endothelial growth factor (VEGF) is a potent mitogen responsible for the induction of angiogenesis (2). VEGF mRNA expression and microvessel density are significantly increased in invasive carcinomas and high-grade intraepithelial lesions compared with low-grade intraepithelial and benign squamous epithelium lesions (3).
High microvessel density is also significantly associated with increased VEGF mRNA expression.
In cases of advanced stage cervical cancer, there are no significant correlations between VEGF mRNA expression and prognostic factors including histological type and lymph node metastasis, although a significant relationship between VEGF mRNA expression and microvessel density was observed (4).
Furthermore, no significant correlation could be demonstrated between VEGF expression and clinicopathological parameters in cases of cervical cancer (5). However, several studies have demonstrated that increased microvessel density and VEGF expression are significantly correlated with poorer prognosis in cases of cervical cancer (6-9).
Bevacizumab, an antibody targeting VEGF, exhibits antitumor properties by inhibiting angiogenesis. Currently, it is used as an effective drug in the treatment of lung, colorectal, and ovarian cancers. Recent research has focused on the effect of bevacizumab against cervical cancer. In the GOG 240 trial, bevacitumab significantly improved the overall survival when added to chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer (10). Moreover, the U.S. Food and Drug Administration (FDA) has approved bevacizumab for use in the patients with aggressive and late-stage cervical cancer (11). Although VEGF can be a target in the treatment of cervical cancer, it is unclear in which cases bevacizumab will be the most effective. Therefore, we investigated potential correlations among VEGF expression, microvessel density, and clinicopathological features in this study to determine whether VEGF expression and microvessel density in invasive cervical cancer lesions are predictive of prognosis. (Fig. 1) .
Materials and Methods

Clinical materials
Semiquantification of immunostaining results
The immunostained sections were semiquantitatively evaluated by investigators who had no knowledge of the clinical status of the patient. VEGF expression in tumor cells was evaluated as previously described (13- 
Microvessel density
According to a previously described method, the sections were 
Statistical analysis
Statistical analysis was performed using Mann-Whitney U tests and Fisher's exact probability tests. The correlation between VEGF expression and microvessel density was examined using the Spearman's rank correlation test. The Kaplan-Meier method and log rank tests were used to clarify whether VEGF expression and microvessel density are predictive of prognosis in cases of cervical cancer.
Results
Correlations between VEGF expression and clinicopathological parameters
VEGF expression was observed in all 50 samples (Figs. 3A,B) .
The average semiquantitative VEGF expression values in cases of squamous cell carcinoma and adenocarcinoma were 4.4 ± 1.8 and 7.3 ± 1.8, respectively, and VEGF expression was significantly higher in adenocarcinomas than in squamous cell carcinomas (P < 0.001; Table 2 ). In addition, elevated VEGF expression was observed in a significantly larger proportion of adenocarcinomas compared with squamous cell carcinomas [88.24% (15 cases) vs. 18.75% (6 cases), P < 0.001; Table 3 ].
However, there were no significant correlations between VEGF expression and the assessed clinicopathological parameters (Table 4) .
Correlations between microvessel density and clinicopathological parameters
Microvessel density was evaluated by detecting CD31-positive cells and counting the corresponding vessels (Figs. 3D,E).
Microvessel density was significantly greater in adenocarcinoma samples than that in squamous cell carcinoma samples (P = 0.013; Table 2 ). In cases of adenocarcinoma, no significant correlations were observed between microvessel density and the assessed clinicopathological parameters. In contrast, microvessel density was significantly greater in squamous cell carcinoma samples than that in advanced stage carcinoma samples and in those with deeper myometrial invasion, vaginal involvement, lymph node metastasis, lymphovascular space invasion, and a high recurrence rate (Table 5) .
Correlations among VEGF expression, microvessel density, and prognosis
A weak but significant correlation was observed between VEGF expression and microvessel density (data not shown). Using the Kaplan-Meier method and log rank tests, no significant correlations were observed between VEGF expression and overall survival or disease-free survival or between microvessel density and overall or disease-free survival. These same results were obtained for both adenocarcinoma and squamous cell carcinoma (data not shown).
Discussion
Angiogenesis plays a key role in tumor growth and metastasis. 
